A Prospective, Controlled Phase II Study of Neoadjuvant Exisulind Therapy Before Radical Prostatectomy: Effect on Apoptosis

Exisulind is a well-tolerated drug with minimal adverse events; however, we were unable to detect any significant differences in apoptotic biomarkers among those treated with neoadjuvant exisulind compared with controls at the dose and duration tested. Future studies should consider evaluating a higher dose or longer duration to better evaluate the role exisulind may play in the treatment of men with CaP.